{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:06:31Z","timestamp":1788959191495,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05182-3","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:44:37Z","timestamp":1787373877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postpartum GLP-1 receptor agonists and SGLT-2 therapies in women with prior gestational diabetes: current evidence and uncertainties"],"prefix":"10.1186","volume":"24","author":[{"given":"Yana","family":"Vanlaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Van de Cauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Embo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-0263","authenticated-orcid":false,"given":"Katrien","family":"Benhalima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"5182_CR1","doi-asserted-by":"publisher","first-page":"1012244","DOI":"10.3389\/fendo.2022.1012244","volume":"13","author":"J Juan","year":"2022","unstructured":"Juan J, Sun Y, Wei Y, Wang S, Song G, Yan J, et al. Progression to type 2 diabetes mellitus after gestational diabetes mellitus diagnosed by IADPSG criteria: Systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:1012244. https:\/\/doi.org\/10.3389\/fendo.2022.1012244.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"5182_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/jcm8091431","volume":"8","author":"K Benhalima","year":"2019","unstructured":"Benhalima K, Lens K, Bosteels J, Chantal M. The risk for glucose intolerance after gestational diabetes mellitus since the introduction of the IADPSG criteria: A systematic review and meta-analysis. J Clin Med. 2019;8(9):1431. https:\/\/doi.org\/10.3390\/jcm8091431.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"5182_CR3","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.2337\/dc23-S015","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S254\u201366. https:\/\/doi.org\/10.2337\/dc23-S015.","journal-title":"Diabetes Care"},{"issue":"3","key":"5182_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.diabres.2007.05.004","volume":"78","author":"HC Gerstein","year":"2007","unstructured":"Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305\u201312. https:\/\/doi.org\/10.1016\/j.diabres.2007.05.004.","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl1","key":"5182_CR5","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.2337\/dc23-S006","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic Targets: Standards of Care in Diabetes\u20142023. Diabetes Care. 2023;46(Suppl1):S97\u2013110. https:\/\/doi.org\/10.2337\/dc23-S006.","journal-title":"Diabetes Care"},{"issue":"1","key":"5182_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4093\/dmj.2021.0335","volume":"46","author":"JH Moon","year":"2022","unstructured":"Moon JH, Jang HC. Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications. Diabetes Metab J. 2022;46(1):3\u201314. https:\/\/doi.org\/10.4093\/dmj.2021.0335.","journal-title":"Diabetes Metab J"},{"key":"5182_CR7","doi-asserted-by":"publisher","first-page":"1391213","DOI":"10.3389\/fgwh.2024.1391213","volume":"5","author":"PC Eng","year":"2024","unstructured":"Eng PC, Teo AE, Der, Yew TW, Khoo CM. Implementing care for women with gestational diabetes after delivery\u2014the challenges ahead. Front Glob Womens Health. 2024;5:1391213. https:\/\/doi.org\/10.3389\/fgwh.2024.1391213.","journal-title":"Front Glob Womens Health"},{"key":"5182_CR8","doi-asserted-by":"publisher","first-page":"180308","DOI":"10.5888\/pcd16.180308","volume":"16","author":"JM Nicklas","year":"2019","unstructured":"Nicklas JM, Rosner BA, Zera CA, Seely EW. Association Between Changes in Postpartum Weight and Waist Circumference and Changes in Cardiometabolic Risk Factors Among Women With Recent Gestational Diabetes. Prev Chronic Dis. 2019;16:180308. https:\/\/doi.org\/10.5888\/pcd16.180308.","journal-title":"Prev Chronic Dis"},{"key":"5182_CR9","doi-asserted-by":"publisher","unstructured":"He J, Hu K, Wang B, Wang H. Effect of dietary and physical activity behavioral interventions on reducing postpartum weight retention among women with recent gestational diabetes: A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(4). https:\/\/doi.org\/10.1111\/obr.13689.","DOI":"10.1111\/obr.13689"},{"key":"5182_CR10","doi-asserted-by":"publisher","unstructured":"Li N, Yang Y, Cui D, Li C, Ma RCW, Li J, et al. Effects of lifestyle intervention on long-term risk of diabetes in women with prior gestational diabetes: A systematic review and meta\u2010analysis of randomized controlled trials. Obes Rev. 2021;22(1). https:\/\/doi.org\/10.1111\/obr.13122.","DOI":"10.1111\/obr.13122"},{"issue":"6","key":"5182_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin","year":"2002","unstructured":"Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512.","journal-title":"N Engl J Med"},{"issue":"4","key":"5182_CR12","doi-asserted-by":"publisher","first-page":"107548","DOI":"10.1016\/j.jdiacomp.2020.107548","volume":"34","author":"KE Elkind-Hirsch","year":"2020","unstructured":"Elkind-Hirsch KE, Shaler D, Harris R. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight\/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study. J Diabetes Complications. 2020;34(4):107548. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107548.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"5182_CR13","doi-asserted-by":"publisher","first-page":"100139","DOI":"10.1016\/j.ajogmf.2020.100139","volume":"2","author":"KE Elkind-Hirsch","year":"2020","unstructured":"Elkind-Hirsch KE, Seidemann E, Harris R. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM. 2020;2(3):100139. https:\/\/doi.org\/10.1016\/j.ajogmf.2020.100139.","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"8","key":"5182_CR14","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13300-021-01104-z","volume":"12","author":"A Jane\u017e","year":"2021","unstructured":"Jane\u017e A, Fioretto P. SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review. Diabetes Therapy. 2021;12(8):2249\u201361. https:\/\/doi.org\/10.1007\/s13300-021-01104-z.","journal-title":"Diabetes Therapy"},{"issue":"10296","key":"5182_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5.","journal-title":"Lancet"},{"key":"5182_CR16","doi-asserted-by":"publisher","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","volume":"14","author":"DRP Muller","year":"2023","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023;14:1215356. https:\/\/doi.org\/10.3389\/fendo.2023.1215356.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5182_CR17","doi-asserted-by":"publisher","unstructured":"Vardhan S, Arnott C, Chen AXN, Frolova A, Meka R, Raghuraman N, et al. Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities. Am J Prev Cardiol. 2026;101471. https:\/\/doi.org\/10.1016\/j.ajpc.2026.101471.","DOI":"10.1016\/j.ajpc.2026.101471"},{"issue":"1","key":"5182_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/dom.15306","volume":"26","author":"S Foghsgaard","year":"2024","unstructured":"Foghsgaard S, Vedtofte L, Andersen ES, Bahne E, Andreasen C, S\u00f8rensen AL, et al. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial. Diabetes Obes Metab. 2024;26(1):201\u201314. https:\/\/doi.org\/10.1111\/dom.15306.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"5182_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","volume":"232","author":"RF Drummond","year":"2025","unstructured":"Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 2025;232(1):17\u201325. https:\/\/doi.org\/10.1016\/j.ajog.2024.08.024.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"5182_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.22270\/jddt.v15i1.6914","volume":"15","author":"V Kumar","year":"2025","unstructured":"Kumar V, Amulya VB, Sharma M, Saikrupa BV. Combination Therapy of SGLT 2 Inhibitors and GLP 1 Receptor Agonists for Glycaemic Management through Weight Reduction. J Drug Deliv Ther. 2025;15(1):142\u20138. https:\/\/doi.org\/10.22270\/jddt.v15i1.6914.","journal-title":"J Drug Deliv Ther"},{"key":"5182_CR21","doi-asserted-by":"publisher","unstructured":"Salamah HM, Marey A, Abugdida M, Abualkhair KA, Elshenawy S, Elhassan WAF, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metabolic Syndrome. 2024;16(1). https:\/\/doi.org\/10.1186\/s13098-024-01371-3.","DOI":"10.1186\/s13098-024-01371-3"},{"issue":"10","key":"5182_CR22","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.2337\/dc21-1785","volume":"45","author":"L Perreault","year":"2022","unstructured":"Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4\u00a0mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022;45(10):2396\u2013405. https:\/\/doi.org\/10.2337\/dc21-1785.","journal-title":"Diabetes Care"},{"issue":"11","key":"5182_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/nejmoa2032183.","journal-title":"N Engl J Med"},{"issue":"10","key":"5182_CR24","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"8","key":"5182_CR25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"5182_CR26","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/oby.23842","volume":"31","author":"L Wilkinson","year":"2023","unstructured":"Wilkinson L, Holst-Hansen T, Laursen PN, Rinnov AR, Batterham RL, Garvey WT. Effect of semaglutide 2.4\u00a0mg once weekly on 10\u2010year type 2 diabetes risk in adults with overweight or obesity. Obesity. 2023;31(9):2249\u201359. https:\/\/doi.org\/10.1002\/oby.23842.","journal-title":"Obesity"},{"issue":"14","key":"5182_CR27","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021;325(14):1403. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"issue":"14","key":"5182_CR28","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"issue":"6","key":"5182_CR29","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1111\/dom.70699","volume":"28","author":"L Ozbek","year":"2026","unstructured":"Ozbek L, Shah E, Al-Shiab R, Inal A, Guldan M, Afsar B, et al. Safety of GLP-1 and Dual GLP-1\/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes Obes Metab. 2026;28(6):4503\u201328. https:\/\/doi.org\/10.1111\/dom.70699.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"5182_CR30","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.clinme.2025.100298","volume":"25","author":"MS Varughese","year":"2025","unstructured":"Varughese MS, O\u2019Mahony F, Varadhan L. GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence. Clin Med (Lond). 2025;25(2):100298. https:\/\/doi.org\/10.1016\/j.clinme.2025.100298.","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"5182_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","volume":"184","author":"CE Cesta","year":"2024","unstructured":"Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024;184(2):144. https:\/\/doi.org\/10.1001\/jamainternmed.2023.6663.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"5182_CR32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.clnu.2024.06.006","volume":"43","author":"Y Belsti","year":"2024","unstructured":"Belsti Y, Moran LJ, Goldstein R, Mousa A, Cooray SD, Baker S, et al. Development of a risk prediction model for postpartum onset of type 2 diabetes mellitus, following gestational diabetes; the lifestyle InterVention in gestational diabetes (LIVING) study. Clin Nutr. 2024;43(8):1728\u201335. https:\/\/doi.org\/10.1016\/j.clnu.2024.06.006.","journal-title":"Clin Nutr"},{"key":"5182_CR33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84314","author":"NM Elfadel Magboul","year":"2025","unstructured":"Elfadel Magboul NM, Mohamed Dkeen NO, Hyder Mohammed HA, Abusin F, Ahmed S, Mohamed Abbas EA, et al. Machine Learning for Predicting the Transition From Gestational Diabetes to Type 2 Diabetes. Syst Rev Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.84314.","journal-title":"Syst Rev Cureus"},{"issue":"24","key":"5182_CR34","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1001\/jama.2025.20951","volume":"334","author":"J Maya","year":"2025","unstructured":"Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, et al. Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA. 2025;334(24):2186. https:\/\/doi.org\/10.1001\/jama.2025.20951.","journal-title":"JAMA"},{"issue":"3","key":"5182_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/AOG.0000000000006161","volume":"147","author":"C Lessard","year":"2026","unstructured":"Lessard C, Cary C, In A, Steinle J, Lin BY, Kablinger AS, et al. Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. Obstet Gynecol. 2026;147(3):290\u20132. https:\/\/doi.org\/10.1097\/AOG.0000000000006161.","journal-title":"Obstet Gynecol"},{"key":"5182_CR36","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.2147\/DMSO.S539822","volume":"18","author":"Z Li","year":"2025","unstructured":"Li Z, Han Z, Sun R, Xuan X, Huang C. Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis. Diabetes Metab Syndr Obes. 2025;18:3611\u201324. https:\/\/doi.org\/10.2147\/DMSO.S539822.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"5182_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1042\/CS20220890","volume":"137","author":"JH Dumolt","year":"2023","unstructured":"Dumolt JH, Rosario FJ, Kramer AC, Horwitz S, Powell TL, Jansson T. Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity. Clin Sci (Lond). 2023;137(8):663\u201378. https:\/\/doi.org\/10.1042\/CS20220890.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"5182_CR38","doi-asserted-by":"publisher","first-page":"E268","DOI":"10.1152\/ajpendo.00361.2023","volume":"326","author":"L Qiao","year":"2024","unstructured":"Qiao L, Lu C, Zang T, Dzyuba B, Shao J. Maternal GLP-1 receptor activation inhibits fetal growth. Am J Physiol Endocrinol Metab. 2024;326(3):E268\u201376. https:\/\/doi.org\/10.1152\/ajpendo.00361.2023.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"5182_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00592-022-01954-4","volume":"60","author":"S Burlina","year":"2022","unstructured":"Burlina S, Dalfr\u00e0 MG, Caprino R, Lapolla A. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetol. 2022;60(1):137\u20138. https:\/\/doi.org\/10.1007\/s00592-022-01954-4.","journal-title":"Acta Diabetol"},{"key":"5182_CR40","doi-asserted-by":"publisher","unstructured":"Hviid KVR, Banasik K, Mortensen LH, Madsbad S, Strandberg-Larsen K, Geiker NRW, et al. Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Hum Reprod Open. 2026;2026(2). https:\/\/doi.org\/10.1093\/hropen\/hoag015.","DOI":"10.1093\/hropen\/hoag015"},{"key":"5182_CR41","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.eclinm.2025.103680","volume":"90","author":"CC Tzang","year":"2025","unstructured":"Tzang CC, Wu PH, Luo CA, Chen ZT, Lee YT, Huang ES, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025;90:103680. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103680.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"5182_CR42","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1097\/MS9.0000000000004189","volume":"87","author":"A Saad Alfaiz","year":"2025","unstructured":"Saad Alfaiz A. GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review. Ann Med Surg (Lond). 2025;87(12):8597\u2013603. https:\/\/doi.org\/10.1097\/MS9.0000000000004189.","journal-title":"Ann Med Surg (Lond)"},{"issue":"Suppl 1","key":"5182_CR43","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.2337\/dc26-S015","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes*","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S321\u201338. https:\/\/doi.org\/10.2337\/dc26-S015.","journal-title":"Diabetes Care"},{"issue":"Suppl1","key":"5182_CR44","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes*","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl1):S183\u2013215. https:\/\/doi.org\/10.2337\/dc26-S009.","journal-title":"Diabetes Care"},{"issue":"17","key":"5182_CR45","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.3390\/NU16172886\/S1","volume":"16","author":"H Diab","year":"2024","unstructured":"Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024;16(17):2886. https:\/\/doi.org\/10.3390\/NU16172886\/S1.","journal-title":"Nutrients"},{"issue":"12","key":"5182_CR46","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1111\/dom.70146","volume":"27","author":"S Murugavel","year":"2025","unstructured":"Murugavel S, Retnakaran R, Feig DS, Zinman B, Kramer CK. Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo\u2010controlled trial. Diabetes Obes Metab. 2025;27(12):7408\u201315. https:\/\/doi.org\/10.1111\/dom.70146.","journal-title":"Diabetes Obes Metab"},{"key":"5182_CR47","unstructured":"National Library of Medicine. Empagliflozin. Drugs and Lactation Database (LactMed). Bethesda (MD). National Library of Medicine (US); 2024."},{"key":"5182_CR48","volume-title":"Drugs and Lactation Database (LactMed)","author":"National Library of Medicine. Dapagliflozin","year":"2024","unstructured":"National Library of Medicine. Dapagliflozin. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2024."},{"issue":"12","key":"5182_CR49","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372. https:\/\/doi.org\/10.1038\/s41569-020-0406-8.","journal-title":"Nat Rev Cardiol"},{"key":"5182_CR50","unstructured":"U.S. Food and Drug Administration. Farxiga (dapagliflozin) prescribing information. 2023."},{"key":"5182_CR51","unstructured":"U.S. Food and Drug Administration. Jardiance (empagliflozin) prescribing information. 2023."},{"key":"5182_CR52","unstructured":"National Library of Medicine. Empagliflozin. Drugs and Lactation Database (LactMed). Bethesda (MD). National Institute of Child Health and Human Development; 2026 . p. 15."},{"key":"5182_CR53","unstructured":"National Library of Medicine. Dapagliflozin. Drugs and Lactation Database (LactMed). Bethesda (MD). National Institute of Child Health and Human Development; 2026 . p. 15."},{"issue":"2","key":"5182_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ando.2022.12","volume":"84","author":"AJ Scheen","year":"2023","unstructured":"Scheen AJ. Dual GIP\/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Ann Endocrinol (Paris). 2023;84(2):316\u201321. https:\/\/doi.org\/10.1016\/j.ando.2022.12. .423 PubMed PMID: 36639119.","journal-title":"Ann Endocrinol (Paris)"},{"key":"5182_CR55","doi-asserted-by":"publisher","first-page":"1004044","DOI":"10.3389\/fendo.2022.1004044","volume":"13","author":"B Gallwitz","year":"2022","unstructured":"Gallwitz B. Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol (Lausanne). 2022;13:1004044. https:\/\/doi.org\/10.3389\/fendo.2022.1004044 . PubMed PMID: 36313764.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"5182_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2018Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"5182_CR57","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251\u201361. https:\/\/doi.org\/10.1007\/s00125-022-05715-4.","journal-title":"Diabetologia"},{"issue":"10295","key":"5182_CR58","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6.","journal-title":"Lancet"},{"issue":"10","key":"5182_CR59","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2410819.","journal-title":"N Engl J Med"},{"key":"5182_CR60","doi-asserted-by":"publisher","first-page":"e118191","DOI":"10.1136\/bmjopen-2026-118191","volume":"16","author":"Y Vanlaer","year":"2026","unstructured":"Vanlaer Y, Embo N, Bochanen N, Van Wilder N, Vereecke G, Wierckx K, et al. Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial. BMJ Open. 2026;16:e118191. https:\/\/doi.org\/10.1136\/bmjopen-2026-118191.","journal-title":"BMJ Open"},{"key":"5182_CR61","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.obmed.2025.100596","volume":"54","author":"R Per\u00e4m\u00e4ki","year":"2025","unstructured":"Per\u00e4m\u00e4ki R, Ollila MM, Hukkanen J, V\u00e4\u00e4r\u00e4sm\u00e4ki M, Uotila J, Metso S, et al. Effect of 52-week liraglutide treatment on diabetes risk and glycaemic control in women with obesity and prior gestational diabetes. A randomized, double-blind, placebo-controlled study. Obes Med. 2025;54:100596. https:\/\/doi.org\/10.1016\/j.obmed.2025.100596.","journal-title":"Obes Med"},{"issue":"17","key":"5182_CR62","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.3390\/nu16172886","volume":"16","author":"H Diab","year":"2024","unstructured":"Diab H, Fuquay T, Datta P, Bickel U, Thompson J, Krutsch K. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients. 2024;16(17):2886. https:\/\/doi.org\/10.3390\/nu16172886.","journal-title":"Nutrients"},{"key":"5182_CR63","doi-asserted-by":"publisher","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne). 2023;14. https:\/\/doi.org\/10.3389\/fendo.2023.1215356.","DOI":"10.3389\/fendo.2023.1215356"},{"issue":"1","key":"5182_CR64","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","volume":"122","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344\u201367. https:\/\/doi.org\/10.1016\/j.ajcnut.2025.04.023.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"5182_CR65","doi-asserted-by":"publisher","first-page":"102038","DOI":"10.1016\/j.beem.2025.102038","volume":"39","author":"A Koceva","year":"2025","unstructured":"Koceva A, Jane\u017e A, Jensterle M. Preconception use of GLP-1 and GLP-1\/GIP receptor agonists for obesity treatment. Best Pract Res Clin Endocrinol Metab. 2025;39(6):102038. https:\/\/doi.org\/10.1016\/j.beem.2025.102038.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"20","key":"5182_CR66","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/jcm11206051","volume":"11","author":"SA Jabbour","year":"2022","unstructured":"Jabbour SA, Ibrahim NE, Argyropoulos CP. Physicians\u2019 Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. J Clin Med. 2022;11(20):6051. https:\/\/doi.org\/10.3390\/jcm11206051.","journal-title":"J Clin Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05182-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:10:59Z","timestamp":1788955859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05182-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5182"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05182-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Microsoft Copilot was used solely for language editing to improve the clarity and readability of the manuscript. The authors reviewed and edited all AI-assisted text and take full responsibility for the content of the manuscript.","order":3,"name":"Ethics","label":"AI statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB received an unrestricted grant and study devices from Medtronic for the investigator-initiated CRISTAL study. KB received study devices from Dexcom for the investigator-initiated GLORIA study. KB received study medication from Novo Nordisk A\/S for the investigator-initiated SERENA study. KB received study devices from Abbott and LifeScan, and a grant from Abbott for the investigator-initiated CORDELIA study. KB received speaker fees from Novo Nordisk, AstraZeneca, and Medtronic. KB was a Guest Editor for the ''''''''Diagnosis and management of gestational diabetes'''''''' collection (special issue on gestational diabetes). All other authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"477"}}